SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Raatikainen Pekka)
 

Sökning: WFRF:(Raatikainen Pekka) > Effect of Catheter ...

  • Blomström-Lundqvist, CarinaUppsala universitet,Kardiologi-arrytmi (författare)

Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients With Atrial Fibrillation : The CAPTAF Randomized Clinical Trial

  • Artikel/kapitelEngelska2019

Förlag, utgivningsår, omfång ...

  • Chicago :American Medical Association (AMA),2019
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-362212
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-362212URI
  • https://doi.org/10.1001/jama.2019.0335DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-157956URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:140554995URI
  • https://gup.ub.gu.se/publication/278572URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • IMPORTANCE Quality of life is not a standard primary outcome in ablation trials, even though symptoms drive the indication. OBJECTIVE To assess quality of life with catheter ablation vs antiarrhythmic medication at 12 months in patients with atrial fibrillation. DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial at 4 university hospitals in Sweden and 1 in Finland of 155 patients aged 30-70 years with more than 6 months of atrial fibrillation and treatment failure with 1 antiarrhythmic drug or beta-blocker, with 4-year follow-up. Study dateswere July 2008-September 2017. Major exclusionswere ejection fraction <35%, left atrial diameter > 60 mm, ventricular pacing dependency, and previous ablation. INTERVENTIONS Pulmonary vein isolation ablation (n= 79) or previously untested antiarrhythmic drugs (n= 76). MAIN OUTCOMES AND MEASURES Primary outcomewas the General Health subscale score (Medical Outcomes Study 36-Item Short-Form Health Survey) at baseline and 12 months, assessed unblinded (range, 0 [worst] to 100 [best]). There were 26 secondary outcomes, including atrial fibrillation burden (% of time) from baseline to 12 months, measured by implantable cardiac monitors. The first 3 months were excluded from rhythm analysis. RESULTS Among 155 randomized patients (mean age, 56.1 years; 22.6% women), 97% completed the trial. Of 79 patients randomized to receive ablation, 75 underwent ablation, including 2 who crossed over to medication and 14 who underwent repeated ablation procedures. Of 76 patients randomized to receive antiarrhythmic medication, 74 received it, including 8 who crossed over to ablation and 43 for whom the first drug used failed. General Health score increased from 61.8 to 73.9 points in the ablation group vs 62.7 to 65.4 points in the medication group (between-group difference, 8.9 points; 95% CI, 3.1-14.7; P=.003). Of 26 secondary end points, 5 were analyzed; 2 were null and 2 were statistically significant, including decrease in atrial fibrillation burden (from 24.9% to 5.5% in the ablation group vs 23.3% to 11.5% in the medication group; difference -6.8%[95% CI, -12.9% to -0.7%]; P=.03). Of the Health Survey subscales, 5 of 7 improved significantly. Most common adverse events were urosepsis (5.1%) in the ablation group and atrial tachycardia (3.9%) in the medication group. CONCLUSIONS AND RELEVANCE Among patients with symptomatic atrial fibrillation despite use of antiarrhythmic medication, the improvement in quality of life at 12 months was greater for those treated with catheter ablation compared with antiarrhythmic medication. Although the study was limited by absence of blinding, catheter ablation may offer an advantage for quality of life.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Gizurarson, SigfusGothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine(Swepub:gu)xgizsi (författare)
  • Schwieler, JonasKarolinska Univ Hosp, Heart & Vasc Theme, Stockholm, Sweden (författare)
  • Jensen, Steen MUmeå universitet,Avdelningen för medicin,Heart Centre, Umeå University, Umeå, Sweden,Umea Univ, Ctr Heart, Umea, Sweden;Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden(Swepub:umu)stje0001 (författare)
  • Bergfeldt, Lennart,1950Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine(Swepub:gu)xbleny (författare)
  • Kennebäck, GöranKarolinska Institutet (författare)
  • Rubulis, Aigars,1974Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine(Swepub:gu)xrubai (författare)
  • Malmborg, HelenaUppsala universitet,Kardiologi-arrytmi(Swepub:uu)helma994 (författare)
  • Raatikainen, PekkaTampere Univ Hosp, Dept Cardiol, Ctr Heart, Tampere, Finland (författare)
  • Lönnerholm, StefanUppsala universitet,Kardiologi-arrytmi(Swepub:uu)stlon912 (författare)
  • Höglund, NiklasUmeå universitet,Avdelningen för medicin,Heart Centre, Umeå University, Umeå, Sweden,Umea Univ, Ctr Heart, Umea, Sweden;Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden(Swepub:umu)niha0025 (författare)
  • Mörtsell, DavidUppsala universitet,Kardiologi-arrytmi(Swepub:uu)davmo383 (författare)
  • Uppsala universitetKardiologi-arrytmi (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:JAMIA Journal of the American Medical Informatics AssociationChicago : American Medical Association (AMA)321:11, s. 1059-10681067-50271527-974X0098-74841538-3598
  • Ingår i:JAMAChicago : American Medical Association (AMA)321:11, s. 1059-10680098-7484

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy